PD-1 蛋白, Human (C93S, HEK293, His)

PD-1 protein, an inhibitory receptor on T-cells, maintains immune tolerance by binding to CD274/PDCD1L1 and CD273/PDCD1LG2. It hinders T-cell activation by associating with CD3-TCR and recruiting PTPN11/SHP-2 for dephosphorylation of key signaling molecules. Tumors exploit PD-1 to weaken anti-tumor immunity, inhibiting CTLs. Blocking PD-1 pathway reverses exhausted T-cell phenotype and enhances anti-tumor response, supporting cancer immunotherapy. PD-1 Protein, Human (C93S, HEK293, His) is the recombinant human-derived PD-1 protein, expressed by HEK293 , with C-6*His labeled tag and C93S mutation. The total length of PD-1 Protein, Human (C93S, HEK293, His) is 143 a.a., with molecular weight of 23-38 kDa.

PD-1蛋白作为抗原激活T细胞的抑制性受体，在诱导和维持自身免疫耐受中发挥着至关重要的作用。 PD-1 与其配体 CD274/PDCD1L1 和 CD273/PDCD1LG2 结合后，会传递抑制信号并与免疫突触中的 CD3-TCR 结合，直接阻碍 T 细胞激活。这种抑制作用通过招募 PTPN11/SHP-2 进一步执行，导致关键 TCR 近端信号分子去磷酸化。 PD-1 与 CD274/PDCD1L1 的相互作用会被肿瘤利用来减弱抗肿瘤免疫力，从而抑制细胞毒性 T 淋巴细胞 (CTL) 效应器功能。阻断 PD-1 介导的通路有望逆转耗尽的 T 细胞表型并使抗肿瘤反应正常化，从而为癌症免疫治疗提供了理论依据。

2 μg/mL (100 μL/well) of immobilized Human PD-1-His can bind Anti-Human PD-1 with an ED50 value of 11.55 ng/mL, corresponding to an affinity constant of 4.97 nM.

Human

HEK293

C-6*His

Q15116 (L25-Q167,C93S)

5133  [NCBI]

LDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDKLAAFPEDRSQPGQDSRFRVTQLPNGRDFHMSVVRARRNDSGTYLCGAISLAPKAQIKESLRAELRVTERRAEVPTAHPSPSPRPAGQFQ

23-38 kDa

Greater than 95% as determined by reducing SDS-PAGE.

无菌粉末.

Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US;may vary elsewhere.